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In this report, we present updated spectrum and frequency of mutations of the CFTR gene that are responsible for cystic fibrosis (CF) in
Languedoc-Roussillon (L-R), the southwestern part of France. A total of 75 different mutations were identified by DGGE in 215 families,
accounting for 97.6% of CF genes and generating 88 different mutational genotypes. The frequency of p.F508del was 60.23% in L-R versus
67.18% in the whole country and only five other mutations (p.G542X, p.N1303K, p.R334W, c.1717-1GNA, c.711+1GNT) had a frequency
higher than 1%. The mutations were scattered over 20 exons or their border. This sample representing only 5.7% of French CF patients
contributed to 24% of CFTR mutations reported in France. This is one of the highest molecular allelic heterogeneity reported so far in CF. We
also present the result of a neonatal screening program based on a two-tiered approach bIRT/20 mutations/IRTQ analysis on blood spots,
implemented in France with the aim to improve survival and quality of life of patients diagnosed before clinical onset. This 18-month pilot
project showed an unexpected low incidence of CF (1/8885) in South of France, with only six CF children detected among 43,489 neonates
born in L-R, and 13 among 125,339 neonates born in Provence-Alpes-Coˆte-d’Azur (PACA).
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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Cystic fibrosis (CF, MIMp219700) remains the most
common life-limiting recessive autosomal disease in Cau-
casian populations. CF is caused by mutations in the Cystic
Fibrosis Transmembrane Conductance Regulator (CFTR;
MIMp602421) gene and is characterized by abnormalities
of secretions of exocrine glands which lead to several
symptoms of variable severity including a progressive
decline in pulmonary function secondary to chronic lung1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.04.008
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65.
E-mail address: Mireille.Claustres@igh.cnrs.fr (M. Claustres).infections, digestive disorders such as pancreatic insuffi-
ciency, infertility in males and elevated chloride concen-
tration in sweat. As of January 2004, a total of 1291
mutations causing or non-causing disease have been
reported to the Cystic Fibrosis Genetic Analysis Consortium
(http://www.genet.sickkids.on.ca/cftr/). The frequency of
these mutations differs tremendously according to the
geographical and ethnic origin of patients, even in the same
country [1]. The accurate knowledge of CFTR mutations
has obvious interest in clinical testing, as it improves CF
prevention programmes of neonatal screening, heterozygote
screening in partners of CF patients or partners of carriers,
and CF diagnosis in prenatal or postnatal circumstances.
Reporting updated data is also crucial in population
genetics, as most papers on CFTR mutation frequencies
and history are compiled from the literature [2,3].3 (2004) 265–272ed by Elsevier B.V. All rights reserved.
M. des Georges et al. / Journal of Cystic Fibrosis 3 (2004) 265–272266We had previously highlighted a remarkable CFTR
allelic heterogeneity in France, by contrast to other countries
in Europe, and a marked difference in the frequency
distribution of the most common mutations among the
geographic regions in France [4]. In the current study, we
have focused extensive and thorough CFTR genotyping of
families with CF residing in the southern French region. The
main aims of the present work were (1) to establish an
updated spectrum of CFTR mutations and genotypes in the
region of Languedoc-Roussillon (L-R), an area of 27,400
km2 extending from the Pyrenean mountains to the
Mediterranean sea and (2) to set up appropriate protocols
and techniques to start a neonatal screening program for CF
in this region. The results revealed that L-R displays one of
the highest allelic heterogeneity described so far, which
poses considerable challenges to the testing laboratory.
Moreover, an 18-month experience of neonatal screening
carried out in the two southern regions of France, L-R (2.3
million inhabitants) and Provence-Alpes-Coˆte-d’Azur
(PACA, 4.6 millions) showed an unexpected low incidence
of CF (1 in 8885) in the Mediterranean border of the
country.2. Materials and methods
2.1. CF population
We have analyzed a total of 229 Caucasian individuals
affected with CF [119 males (51.96%), 110 females
(48.04%) including two monozygotic female twins] from
215 families not known to be related, who were born and/or
residing in L-R at the time of study. We included in this
report only patients with diagnosis of classic CF based on
typical clinical criteria and two positive sweat tests (cut-off,
60 mmol/l). The molecular diagnosis relied on the compre-
hensive scanning of exons and surrounding intronic
sequences by Denaturing Gradient Gel Electrophoresis
(DGGE, set up in our laboratory since 1993) followed by
the sequencing of PCR products displaying altered migra-
tion pattern. In all cases, a familial study was performed to
follow the segregation of alleles. The cost of CFTR
scanning in our region (L-R) was covered by a special
grant from the French Health Ministry.
2.2. Neonatal screening
A neonatal screening program for CF was implemented in
June 2002 in L-R (2.3 million inhabitants) by means of
immunoreactive trypsinogen (IRT) determinations and
genetic analysis using Guthrie cards with an informed
consent required for all the babies. The protocol was based
on a two-tier method. Blood was taken from neonate’s heel at
3 days of age and immunoreactive trypsinogen (IRT) was
assayed by radioimmunological method from dried blood
spots (Guthrie cards). If the IRT concentration was greaterthan 60 ng/ml (from June 2002 to February 2003) or 65 ng/ml
(from March 2003), the same blood spot card was subjected
to the genetic test. The 20 most common mutations
responsible for CF worldwide were investigated by amplifi-
cation refractory mutation system (ARMS) and migration on
agarose gel (Kit Elucigene CF20, including mutations
c.1717-1GNA, p.G542X, p.W1282X, p.N1303K, p.F508del,
c.3849+10kbCNT, c.621+1GNT, p.R553X, p.G551D,
p.R117H, p.R1162X, p.R334W, p.A455E, c.2183AANG,
c.3659delC, c.1078delT, p.I507del, p.R347P, p.S1251N,
p.E60X). This test detected 77.9% of mutations responsible
for CF in our CF population. If no mutation was found,
the subjects positive at the first IRT were retested for IRT
at 21 days of age (cutoff of 40 ng/ml). Newborns with two
CFTR mutations and a positive sweat test (chloride
concentration greater than 60 mmol/l) were referred with
a definite diagnosis of CF. Infants with only one mutation
or those who had no identified mutation and an IRT level
at 21 days of age greater than 40 ng/ml were subjected to a
sweat test. If the sweat test was negative, the baby was
regarded as non-CF (carrier or no mutation detected). If
the sweat test was positive, the neonate was considered as
CF and the laboratory searched for CFTR mutations on a
new peripheral blood sample through the DGGE scanning
of CFTR exons and flanking regions. Babies with no
mutation and a sweat test value higher than 40 mmol/l and
babies with one mutation and a sweat test value greater
than 30 mmol/l were regarded as possible CF patients and
were enrolled for further clinical investigations by the
Regional CF center in order to confirm or invalidate the
diagnosis of CF. Newborns who were positive to the
screening were enrolled by the Regional CF center for
further clinical investigations and the family was offered
genetic counselling. A similar screening programme was
also implemented in the other Mediterranean region,
Provence-Alpes-Coˆte d’Azur (bPACAQ, 4.5 million inhab-
itants), with our laboratory involved in CFTR mutation
analysis.
2.3. Nomenclature
Gene variants, mutants and mutational genotypes
were named as recommended in the Human Genome
Variation Society web page (http://www.genomic.unimelb.
edu.au/mdi/).3. Results
3.1. Spectrum of CFTR mutations and genotypes
responsible for CF in L-R
In 215 CF patients, a total of 75 different mutations
scattered all over the CFTR gene were identified, account-
ing for 97.6% of CF alleles (Table 1). The main mutation,
p.F508del, was present in 60.23% of chromosomes versus
Table 1
Frequencies of CFTRmutations identified in 215 patients with cystic fibrosis
originating from Languedoc-Roussillon, diagnosed on a clinical basis
Mutation Location
exon/intron
No. of chromosomes
(frequency %)
p.M1V 1 1 (0.23)
p.M1K 1 1 (0.23)
c.300delA 3 1 (0.23)
p.P67L 3 1 (0.23)
c.359insT 3 1 (0.23)
p.G85E 3 3 (0.70)
c.394delTT 3 1 (0.23)
p.Q98R 4 1 (0.23)
p.R117H 4 2 (0.47)
p.Y122X 4 2 (0.47)
p.Y161N 4 1 (0.23)
c.621+1GNT intron 4 1 (0.23)
c.621+2TNG intron 4 1 (0.23)
p.I175V 5 2 (0.47)
c.711+1GNT intron 5 5 (1.16)
p.L206W 6 3 (0.70)
p.Q220X 6 1 (0.23)
p.L227R 6 1 (0.23)
c.1078delT 7 2 (0.47)
p.R334W 7 7 (1.63)
p.R347P 7 2 (0.47)
c.1215delG 7 1 (0.23)
c.T5 intron 8 1 (0.23)
p.D443Y 9 1 (0.23)
p.I506T 10 1 (0.23)
p.I507del 10 4 (0.93)
p.F508del 10 259 (60.23)
p.F508C 10 1 (0.23)
c.1677delTA 10 1 (0.23)
c.1717-8GNA intron 10 1 (0.23)
c.1717-1GNA intron 10 6 (1.40)
p.G542X 11 23 (5.35)
p.S549R 11 1 (0.23)
p.G551D 11 2 (0.47)
p.R553X 11 1 (0.23)
c1811+1.6kbANG intron 11 4 (0.93)
c.1812-1GNA intron 11 1 (0.23)
p.T582I 12 1 (0.23)
p.E585X 12 2 (0,47)
c.1898+1GNA intron 12 1 (0.23)
[c.1898+5GNA ;p.E725K] intron 12 1 (0.23)
c.1898+73TNG intron 12 1 (0.23)
c.2183AANG 13 4 (0.93)
c.2184insA 13 1 (0.23)
p.K710X 13 4 (0.93)
c.2423delG 13 1 (0.23)
p.S776X 13 1 (0.23)
c.2493ins8 13 1 (0.23)
p.R792X 13 1 (0.23)
p.K830X 13 1 (0.23)
p.D836Y 14a 1 (0.23)
p.W846X1 14a 1 (0.23)
c.2711delT 14a 1 (0.23)
c.2789+5GNA intron 14b 3 (0.70)
p.S945L 15 3 (0.70)
p.D993Y 16 1 (0.23)
c.3129del4 17a 1 (0.23)
c.3195del6 17a 1 (0.23)
c.3272-26ANG intron 17a 1 (0.23)
[c.3395insA ;pI148T] 17b/4 1 (0,23)
p.Y1092X 17b 3 (0.70)
Table 1 (continued)
Mutation Location
exon/intron
No. of chromosomes
(frequency %)
p.E1104X 17b 2 (0.47)
p.R1158X 19 3 (0.70)
p.R1162X 19 2 (0.47)
c.3659delC 19 1 (0.23)
c.3737delA 19 2 (0.47)
p.I1234V 19 1 (0.23)
c.3849+10kbCNT intron 19 4 (0.93)
c.3850-1GNA intron 19 1 (0.23)
p.G1244E 20 1 (0.23)
p.W1282X 20 2 (0.47)
p.N1303H 21 1 (0.23)
p.N1303K 21 13 (3.02)
p.Q1313X 21 1 (0.23)
c.4382delA 24 1 (023)
Mutations described for the first time by our laboratory appear in bold.
Variants are described using DNA and protein designation: intronic
changes, deletions, insertions and frameshifts are reported at the cDNA
level (c.) and amino acid changes at the protein level (p.).
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were found with a relative frequency higher than 1%:
p.G542X (5.35%), p.N1303K (3.02%), p.R334W (1.63%),
c.1717-1GNA (1.40%) and c.711+1GNT (1.16%) (Table 1).
From Fig. 1, it can be seen that mutations p.G542X,
p.N1303K, p.R334W and c.711+1GNT are more common in
Mediterranean areas than in the whole country. Twenty-two
mutations found on 2–4 chromosomes and 47 mutations
found on only one chromosome accounted for 13.95% and
10.93% of CF alleles, respectively. Overall, 24/75 mutations
(32%) were described by our laboratory for the first time
(CF Genetic Analysis Consortium web page) (Table 1). Ten
alleles (2.33%) remained uncharacterized after complete
scanning of the whole 27 exons/flanking sequences and
additional screening for three common mutations
(c.1811+1.6kbANG, c.3849+10kbCNT, allele 5T in IVS8)
and a large deletion (CFTR del 2,3).
The 75 detected mutations generated 88 different
mutational genotypes. Three genotypes were responsible
for approximately half the cases of CF: p.F508del+
p.F508del (39.06%), p.F508del+p.G542X (6.51%) and
p.F508del+p.N1303K (3.26%). By contrast, these geno-
types accounted for 47.75%, 3.4% and 2.7%, respec-
tively, in a sample of 3,170 CF patients who had been
genotyped in France in 2000 [4]. 42.32% of CF patients
in the present study carried one p.F508del associated with
another mutation and 16.75% carried two other muta-
tions. In one patient (0.46%), no causative mutation was
found despite extensive scanning. A diagnosis of CF
occurred in 87.4% of all patients before their 10th
birthday (with 60.74% diagnosed before 1 year of age).
Four patients were diagnosed at age 30, 32, 34 and 41
years and the extreme age at diagnosis was 70 years, in a
male who was diagnosed initially for bronchiectasis and
was carrying a 5T allele in trans of a novel missense
T582I. 61.3% of patients homozygous for p.F508del and
Fig. 1. Distribution of the most common mutations (frequencyN1%) in southern France and in the whole country (in bold, mutations typical of
Mediterranean areas).
Table 2
Genotypes identified by newborn screening in 19 affected babies
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mutation were diagnosed before 6 months, whereas
86.5% of patients carrying either a severe or mild allele
in combination with a mild or unknown mutation were
diagnosed after 6 months (Fig. 2).
3.2. Neonatal screening in the two Mediterranean regions of
France: L-R and PACA
Between June 2002 and December 2003, 168,828
newborns were screened for CF in L-R and PACA. The
IRT-1 concentrations were higher than the cutoff in 1299
samples (0.77%) and were followed by the genetic test
which detected 11 cases with two mutations: eight were
homozygous for the mutation p.F508del, two were com-Fig. 2. Age at diagnosis of the CF patients in Languedoc-Roussillon
according to genotype.pound heterozygotes (p.I507del+p.R334W and p.G542X+
p.R117H) and one was homozygous for the mutation
p.R117H associated with the 7T allele in the intron 8
polythymidine sequence (IVS8) (Table 2).
Seventy-nine newborns in whom only one mutation was
identified were referred to the regional CF center. Among
them, six cases were diagnosed as having CF because of a
positive sweat test. The second mutation responsible for CF
was detected by DGGE scanning followed by sequencing of
PCR products displaying an abnormal pattern. Six rare
mutations were identified: c.3007delG, c.2622+1GNA and
c.3850-1GNA in trans of the mutation p.F508del, c.2380del8IRT (ng/ml) Genotypes
118 [p.F508del]+[p.F508del]a
163 [p.F508del]+[p.F508del]a
N130 [p.F508del]+[p.F508del]b
N130 [p.F508del]+[p.F508del]b
N130 [p.F508del]+[p.F508del]b
155 [p.F508del]+[p.F508del]a
166 [p.F508del]+[p.F508del]a
109 [p.F508del]+[p.F508del]a
110 [p.F508del]+[p.F508del]a
136 [p.F508del]+[c.3007delG]a
160 [p.F508del]+[c.2622+1GNA]a
129 [p.F508del]+[c.3850-1GNA]a
151 [p.G542X]+[c.2380del8]a
131 [c.1078delT]+[p.K710X]a
N130 [p.I507del]+[p.R334W]b
75 [p.G542X]+[p.R117H ;c1342-6 T7]b
MI [p.E1104X]+[p.E1104X]b
84 [p.R117H; c1342-6 T7]+[p.R117H;
c1342-6 T7]a
99 [c.2183AANG]+[p.Q220X]a
IRT: Immunoreactive trypsinogen (cutoff: 65 ng/ml).
MI: Meconium ileus.
a Babies born in PACA.
b Babies born in LR.
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p.Q220X in trans of c.2183AANG (Table 2).
In 72 cases out of 1280, the sweat test was negative and
the babies were regarded as heterozygotes (frequency 1/
17.7). The mutation was p.F508del (n=47), p.G542X (n=5),
p.N1303K (n=4), p.G551D (n=2), p.R334W (n=2), c.1717-
1NA (n=1), p.I507del (n=1), p.R1162X (n=1),
[p.R117H;IVS8-T7] (n=8) or [p.R117H;IVS8-T5] (n=1).
One case with borderline sweat test value (42 mmol/l) and
genotype p.N1303K+unknown will be further investigated.
A neonate with IRT above 130 ng/ml at 3 days of age
was not referred to the molecular laboratory because the
parents refused consent. This child was later detected as
being affected with CF on the basis of clinical symptoms
(ileal obstruction and bowel perforation) then positive sweat
tests (115 and 125 mmol/l). After complete DGGE scanning
followed by the sequencing of exon 17b, this neonate born
from consanguineous parents of North African descent was
found to be homozygous for the mutation p.E1104X.
Another case presented with meconium ileus at birth and
was diagnosed clinically; a blood sample was directly
referred at 7 days of age to the genetic laboratory and
homozygosity for p.F508del was found. A first cousin of the
mother was affected with CF, but cascade genetic screening
had not been proposed to the relatives.
All other 1206 children with IRT-1 positive values and
no mutation detected were retested for blood IRT at 21 days
of age. The babies with positive IRT-2 were referred to the
regional CF center and, at this time, all sweat tests done
were negative.Fig. 3. Incidence of cystic fibrosis (iCF) in th3.3. Refined risk calculations
The neonatal screening program implemented in South-
ern France allowed the identification of six CF-affected
children among 43,489 newborns screened in L-R from
June 2002 to December 2003 and 13 CF-affected children
among 125,339 newborns screened in PACA from April
2002 to December 2003. The incidence of CF in popula-
tions living in the two French Mediterranean regions is
therefore only 1 in 8885 live births (Fig. 3). According to
these data, the CF allele frequency is 0.0106, corresponding
to an expected CF carrier frequency of 1 in 47. Given the
mutation detection rate of 97.6% after complete DGGE
scanning of CF sequences and taking into account the
corrected incidence of CF after neonatal screening, the
residual risk of carrying a mutation or of having an affected
child after a negative mutation test can be calculated as
indicated in Table 3.4. Discussion
4.1. Increased diversity of CFTR mutations in Languedoc-
Roussillon (L-R)
This study shows that the spectrum of CF-causing
mutations observed in L-R is different from the one reported
for the entire country [4]. The proportion of p.F508del is
lower than that observed in the whole country and some
mutations found with relative frequency higher than 1% ine two Mediterranean regions of France.
Table 3
CF-related risk after mutation analysis for carrier status in LR and PACA as modified by neonatal screening data
Percentage of CF
mutations detectable
Carrier risk (Z)a for individuals with negative test Risk of CF in offspring for couples tested
One parent positive (Z/4) Neither parent positive (Z2/4)
Frenchb LR/PACAc French LR/PACA French LR/PACAg
Not tested 1/30 1/47 Not applicable Not applicable 1/3500 1/8885
OLA 31 mutationsd 1/171 1/243 1/684 1/972 1/116,964 1/236,196
Elucigene CF20e 1/153 1/201 1/5612 1/804 1/93,636 1/161,604
Complete scanningf 1/1219 1/1920 1/4876 1/7680 1/5,943,844 1/14,745,600
a Z=q(1-a)/(1-aq) with q=carrier frequency in a given population and a=sensitivity of the test, i.e. proportion of mutant CFTR alleles in a given population
that can be identified with the test.
b Mean frequency for CF carriers in France.
c Mean frequency for CF carriers in LR and PACA, based on the first 18 months of CF neonatal screening.
d a=81% in LR-PACA and 83% in France.
e a=77% in LR-PACA and 81% in France.
f a=97.5% in LR-PACA and in France (complete DGGE scanning of CFTR exons and flanking sequences).
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Northern France, c.1078delT, p.G551D and p.W846X in
Brittany, or c3905insT in Eastern France [4] were found at
very low rates in South. The L-R region showed one of the
highest allelic heterogeneity reported so far, with 75
different mutations identified in 215 CF families. By
comparison, only 80 different mutations were found in a
recent study of 437 CF patients extensively genotyped by
DGGE in Greece [5]. In Southern Italia, searching for only
13 mutations covered 85% of CF alleles in a sample of a
similar size as ours [6].
L-R is a region of 2.3 million inhabitants, with an
average annual birth cohort ranging from 29,000 to 30,000
newborns. In the course of the last century, the demo-
graphics of L-R has been unstable and ethnic mixing
happened. The last return of population (1999) showed that
126,000 (5.7%) individuals were bFrench with recent
foreign originQ and 131,000 (5.9%) were not French;
including Moroccan (43,500), followed up by Spanish
(23,600), Algerian (14,000), Portuguese (9000), Italian
(4000), Turkish and Tunisian (more than 2000 in each
group) and other populations (N30,000 European, African
and Asian). These data were confirmed in a recent report on
HFE mutations [7] where the author could study the ethnic
background in a sample of 1272 newborns obtained from
four main hospital maternity of L-R. Among them, only
43.5% had four grandparents of French origin and 14.8%
had all four grandparents originating from North Africa. The
remaining group included babies originating from various
European, African or Asian countries. This important
population admixing could explain the lower frequency of
CF among neonates but cannot explain the higher allelic
heterogeneity in this region. According to a recent study, the
major factor that contributed to the CF mutation diversity is
the size of ancestral population [3]. It is believed that at the
postglaciation phase and later during the Neolithics,
population expansion has started earlier, and then expanded
much faster and more extensively along the Mediterranean
shores than in northern parts of Europe, presumably due to
more favourable living conditions [3].As reported by many laboratories, some mutants (2.4%
of alleles) remain uncharacterized after screening of the
whole coding and flanking CFTR sequences. They might be
located in regions not investigated (promoter, 3V untrans-
lated or intronic regions). In addition, although DGGE is
highly sensitive and specific, we cannot exclude that some
nucleotides residing in higher melting domains have been
missed. Heterozygous deletions, insertions or inversions
spanning a complete exon or more would not be detected by
standard PCR-based scanning methods.
4.2. Improved neonatal screening
From June 2002, we used a commercially available kit
including the 20 most frequent mutations worldwide (Eluci-
gene CF20). This kit has a detection rate of 77.9% in L-R
versus 81% in France. Extensive mutation analysis in L-R
was essential to know the spectrum of CFTR sequence
anomalies and to design a kit with a better detection rate. A
new bFrench kitQ with 10 additional mutations is in
production and this panel will include mutation subsets
shown to be frequent in some areas and/or populations. In
southern France, 4 of these 10 additional mutations have a
relative frequency above 0.5%: c.711+1GNT (1.16%),
c.1811+1.6kbANG (0.93%), c.2789+5GNA (0.70%) and
p.Y1092X (0.70%). The panel of 30 mutations (c.1717-
1GNA, p.G542X, p.W1282X, p.N1303K, p.F508del,
c.3849+10kbCNT, c.621+1GNT, p.R553X, p.G551D,
p.R117H, p.R1162X, p.R334W, p.A455E, c.2183AANG,
c.3659delC, c.1078delT, p.I507del, p.R347P, p.S1251N,
p.E60X, p.Y1092X, c.394delTT, c.1811+1.6kbANG,
c.3272-26ANG, c.2789+5GNA, c.3120+1GNA, c.711+
1GNT, p.G85E, p.Y122X, p.W846X) should account for
83.32% of the CF alleles in L-R and 84.25% in the whole
country.
4.3. Incidence of CF in southern France
So far, CF was expected to affect about 1 in 3500
individuals in France (French National CF Observatory).
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ing showed that of the 43,489 births in L-R, six children
with CF were identified, giving an unexpected low
incidence of CF at birth of 1/7248. We obtained similar
figures in the region PACA, with 13 cases (1/9641)
diagnosed as CF among 125,339 neonates screened during
20 months (from April 2002 to December 2003). By
contrast, Brittany, a region of 2.8 million inhabitants of
mostly Celtic origin where CF is very common, presents
one of the highest birth prevalence of CF observed
throughout the world [8]. Indeed, the neonatal screening
program implemented in Brittany 13 years ago identified
123 CF-affected children among 349,072 newborns
screened between January 1992 and December 2001; the
prevalence of CF at birth was therefore 1/2838 over a 10-
year period in this part of the country [9].
The high allelic heterogeneity in our region could be
responsible for milder forms of CF with normal neonatal
IRT concentrations that could contribute to find a very low
incidence in neonatal screening. This hypothesis is in
agreement with data of the French National CF Observ-
atory which showed that 50% of children were diagnosed
before 4 months of age [10]. In the sample of 215 CF
patients from L-R, the age at diagnosis was reported in
150 files and only 46.6% were diagnosed before 6 months.
These data could confirm the hypothesis of milder or
different phenotypes in Mediterranean regions. Similar data
were reported in a recent study on phenylketonuria in
which the author showed a high frequency of severe PKU
in central and eastern European countries and a high
proportion of severe mutations and milder forms in
Mediterranean regions [11].
4.4. Hypertrypsinemia and CF heterozygotes
From 18 months of neonatal screening, an incidence of
CF of 1 in 8885 live births leads us to an estimated carrier
frequency of 1/47 (2.12%) assuming Hardy–Weinberg
equilibrium. Over the same period, 72 children carrying
one CFTR mutation were detected among 1280 neonates
with positive IRT (1/17.7=5.65%), i.e., 2.7 times greater
than the expected frequency. These data are in agreement
with previous neonatal screening programs that have
reported the identification, among neonates with hyper-
trypsinaemia, of a CF carrier frequency three times higher
than expected in the general population [12–14]. At this
time, the underlying mechanism of selection of carriers by
the neonatal programme remains obscure. Some of these
children with hypertrypsinaemia, only one mutation
detected and a borderline sweat test may present atypical
CF (bronchiectasis, congenital absence of the vas deferens,
pancreatitis, etc.) and it has been recently suggested that
these patients should be reevaluated to avoid late diagnosis
[13]. Assessment of chloride conductance in respiratory
and intestinal tissues by determination of nasal potential
difference and intestinal current measurements may repre-sent a useful diagnostic adjunct to precise the status of
these babies [15]. It has been proposed that children who
may later in life develop moderate or minimal CF be
regarded as bpre-CFQ [16]. It would be of great interest to
know the benefit and the psychological impact of a clinical
long-term follow-up in infant with mild or atypical CF
with regard to a possible prevention of a hypothetic
chronic lung disease in adulthood.
We found the frequency of mutation R117H (12.16%)
higher in the heterozygous neonates than in the CF
population in France (0.16%) or in L-R (0.47%). R117H-
7T is associated with a broad phenotypic range, from CF
with suppurative lung disease to no clinical disease.
Extended follow-up will be required to determine whether
clinical manifestations are associated with mild CFTR
mutations. One can wonder whether newborn screening
should be confined to classical mutations associated with
severe disease or whether it should be enlarged in order to
diagnose mild or atypical forms of the disease and to help in
the knowledge of rare or phenotypically variable mutations.
4.5. Refinement of risks for accurate genetic counselling
Risk calculations are usually based on the estimated 1/
2500 mean incidence of CF in Caucasian populations. The
results of our pilot neonatal screening revealed that incidence
of CF at birth in Mediterranean areas is about 1/9000. This
information will have to be taken into account by genetic
counsellors charged with providing couples with information
concerning residual risks, particularly in the context of
couples where a bowel echogenicity is detected during
ultrasonography examination or couples with a partner
related to a CF patient. In France, neonatal screening for
genetic disease is intended to reduce childhood morbidity
and mortality through early identification and treatment of
affected infants [17,18] although it is still a matter of debate
[19]. It is not primarily intended to offer prenatal screening
of subsequent pregnancies in couples with an affected child.
Neonatal screening in France does not include any informa-
tion on the ethnic or geographic origin of parents, so that it is
impossible to accurately calculate residual risks of CF in the
different ethnic communities living in the country.
On the whole, regarding the large CFTR allelic hetero-
geneity in Southern France, it is important to continue to
retest IRT at 21 days in babies without mutations and an IRT
at 3 days of age greater than 100 ng/ml. In conclusion, this
study demonstrates that, even within a single country, it is
desirable to have a detailed knowledge of specific regional
CF-causing mutations if we want to offer the most efficient
screening strategy.Acknowledgements
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